PAVmed (NASDAQ:PAVM) Stock Price Passes Below 50-Day Moving Average – Should You Sell?

PAVmed Inc. (NASDAQ:PAVM) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $5.50 and traded as low as $4.89. PAVmed shares last traded at $5.20, with a volume of 9,380 shares traded.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a research note on Friday, July 17th. Ascendiant Capital Markets decreased their price objective on PAVmed from $65.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Finally, Wall Street Zen raised PAVmed from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $56.00.

PAVmed Stock Performance

The company’s fifty day moving average price is $5.45 and its two-hundred day moving average price is $7.86. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.02. The firm has a market capitalization of $5.10 million, a PE ratio of -0.14 and a beta of 0.54.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.48). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.07 million. PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%. As a group, equities analysts expect that PAVmed Inc. will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in PAVmed stock. Geode Capital Management LLC boosted its position in PAVmed Inc. (NASDAQ:PAVM) by 74.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 168,832 shares of the company’s stock after acquiring an additional 72,258 shares during the quarter. Geode Capital Management LLC owned 17.23% of PAVmed worth $40,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.